About Cabozantinib HCl API

Mechanism of Action

Cabozantinib is a tyrosine kinase inhibitor that acts by blocking the activity of multiple tyrosine kinases, including MET and VEGFR2. Tyrosine kinases are enzymes that play a key role in signaling pathways that regulate cellular processes such as proliferation, migration, and angiogenesis.

In cancer, these signaling pathways are often dysregulated, leading to uncontrolled cell growth and survival. By inhibiting the activity of these kinases, cabozantinib can block these signaling pathways and potentially slow or stop the growth of cancer cells.

Specifically, cabozantinib has been shown to effectively inhibit the activity of MET, a tyrosine kinase that is overexpressed in many cancers and plays a key role in tumor growth, invasion, and angiogenesis. Inhibition of VEGFR2, another target of cabozantinib, can also block the growth of new blood vessels that tumors need to grow and spread.

Overall, the mechanism of action of cabozantinib involves blocking the activity of multiple tyrosine kinases involved in cancer cell growth and survival, ultimately leading to the inhibition of tumor growth.

Indication

Cabozantinib is an FDA-approved treatment for several types of cancer. It is indicated for the following indications:

Metastatic Renal Cell Carcinoma (mRCC): Cabozantinib is indicated for the treatment of patients with advanced or metastatic renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

Medullary Thyroid Cancer (MTC): Cabozantinib is indicated for the treatment of patients with locally advanced or metastatic medullary thyroid cancer (MTC) who require systemic therapy and have received prior treatment with radioactive iodine.

Hormone-Relapsed Prostate Cancer: Cabozantinib is indicated for the treatment of patients with hormone-relapsed prostate cancer that has progressed during or after androgen deprivation therapy.

Advanced Liver Cancer: Cabozantinib is indicated for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Dr. Reddy’sの専門知識・技術

ハイデラバード（インド）に本社を構えるDr. Reddy’s Laboratoriesは、世界的に有名な原薬（API）供給業者です。Dr. Reddy’sのAPIビジネスは米国、ヨーロッパ、ブラジル、南米、日本、中国、韓国、その他の新興市場において製薬会社の推奨パートナーとなっています。

Dr. Reddy’sのAPIビジネスは、ステロイド、ペプチド、複合長鎖分子、高薬理活性API（HPAPI /腫瘍学薬）など、複合APIの開発・製造において、30年以上にわたり高度な技術的実績を築き上げ、成長しています。この専門知識・技術は弊社の知的財産および規制関連業務の実績と共に、一貫して規制基準を満たし、それを超える優れた価値を生み出しています。Dr. Reddyの(-) API, R&D (研究開発)、IP、規制の高度な専門知識・技能の結果です。

顧客が真っ先に市場に参入するのに重要な要素は、機敏な供給網です。弊社は全施設を効率的に、そしてコストを最適化して稼働させ、品質と安全性、また、生産性の最新基準に従うことで、そうした供給網を実現させます。オフィスと工場の結びつきを強化し、ダイナミックな市場の変化に迅速に対応しています。そうした理由から、弊社は不足を解消して突発的な供給を満たすことができるのです。